Clíona Grant

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +11

Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma

Kieron Dunleavy, Stefania Pittaluga, Lauren S. Maeda et al. · New England Journal of Medicine · 2013 · 561 citations · Full text

Medicine, Immunology, Oncology +15

Low-Intensity Therapy in Adults with Burkitt's Lymphoma

Kieron Dunleavy, Stefania Pittaluga, Margaret Shovlin et al. · New England Journal of Medicine · 2013 · 360 citations · Full text

Medicine, Oncology, Pharmacology +9

Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma

Nakhle S. Saba, Delong Liu, Sarah E. M. Herman et al. · Blood · 2016 · 165 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Kevin J. Harrington, Robert L. Ferris, Maura L. Gillison et al. · JAMA Oncology · 2023 · 72 citations · Full text

Medicine, Oncology, Pharmacotherapy +17